Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme

Authors

  • Wei Zhang MD,

    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Search for more papers by this author
    • The first 2 authors contributed equally to this work.

  • Jing Zhang PhD,

    1. Laboratory of Disease Genomics and Individualized Medicine, Center of Computational Biology, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
    Search for more papers by this author
    • The first 2 authors contributed equally to this work.

  • Wei Yan MD,

    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Search for more papers by this author
  • Gan You MD,

    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Search for more papers by this author
  • Zhaoshi Bao MD,

    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Search for more papers by this author
  • Shouwei Li MD,

    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    Search for more papers by this author
  • Chunsheng Kang MD,

    1. Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, China
    Search for more papers by this author
  • Chuanlu Jiang MD,

    1. Department of Neurosurgery, Harbin Medical University Second Affiliated Hospital, Harbin, China
    Search for more papers by this author
  • Yongping You MD,

    1. Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
    Search for more papers by this author
  • Yuxiang Zhang MD,

    1. Department of Biochemistry and Molecular Biology, College of Basic Medical Science, Capital Medical University, Beijing, China
    Search for more papers by this author
  • Clark C. Chen MD,

    1. Division of Neurosurgery, University of California at San Diego, San Diego, California
    Search for more papers by this author
  • Sonya Wei Song PhD,

    Corresponding author
    1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
    • Sonya Wei Song, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China

      Tao Jiang, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

    Search for more papers by this author
    • Fax: (011) 861088196764

  • Tao Jiang MD

    Corresponding author
    1. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
    • Sonya Wei Song, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China

      Tao Jiang, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

    Search for more papers by this author
    • Fax: (011) 861067021832


Abstract

BACKGROUND:

More reliable clinical outcome prediction is required to better guide more personalized treatment for patients with primary glioblastoma multiforme (GBM). The objective of this study was to identify a microRNA expression signature to improve outcome prediction for patients with primary GBM.

METHODS:

A cohort of Chinese patients with primary GBM (n = 82) was analyzed using whole-genome microRNA expression profiling with patients divided into a training set and a testing set. Cox regression and risk-score analyses were used to develop a 5-microRNA signature using 41 training samples. The signature was validated in 41 other test samples, in an independent cohort of 35 patients with GBM, and in the Cancer Genome Atlas data set.

RESULTS:

Patients who had high risk scores according to the 5-microRNA signature had poor overall survival and progression-free survival compared with patients who had low risk scores. Multivariate Cox analysis indicated that the 5-microRNA signature was an independent prognostic biomarker after adjusting for other clinicopathologic and genetic factors, such as extent of resection, temozolomide chemotherapy, preoperative Karnofsky performance status score, isocitrate dehydrogenase 1 (IDH1) mutation, and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status.

CONCLUSIONS:

The 5-microRNA signature was identified as an independent risk predictor that identified patients who had a high risk of unfavorable outcome, demonstrating its potential for personalizing cancer management. The authors concluded that this signature should be evaluated in further prospective studies. Cancer 2013. © 2012 American Cancer Society.

Ancillary